Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 11/20 | 0.52 |
| ▸ | THRA | P10827 | 8/20 | 0.52 |
| ▸ | RORC | P51449 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042751 | 0.85 | THRA (0.56) | THRBTHRA | |
| SCHEMBL5047511 | 0.85 | THRB (0.48) | THRBTHRARORC | |
| SCHEMBL7073367 | 0.83 | THRB (0.56) | THRBTHRARORC | |
| SCHEMBL2047460 | 0.82 | THRB (0.51) | THRBTHRARORC | |
| SCHEMBL11039034 | 0.78 | RORC (0.47) | THRBTHRARORC | |
| SCHEMBL5283822 | 0.78 | THRB (0.57) | THRBTHRARORC | |
| SCHEMBL5045360 | 0.78 | THRA (0.49) | THRBTHRACYP1A2 | |
| SCHEMBL4965062 | 0.76 | THRB (0.48) | THRBTHRARORC | |
| SCHEMBL5041618 | 0.76 | THRA (0.45) | THRBTHRACYP1A2 | |
| SCHEMBL14264303 | 0.75 | THRA (0.39) | THRBTHRACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| US-7342127-B2 | Substituted anilide ligands for the thyroid receptor | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1601641-A4 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL MYERS SQUIBB CO (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1601641-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | Bristol-Myers Squibb Company (US) | 2005-12-07 | — | — | EP | disclosed |
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | KARO BIO AB (SE) | 2004-09-16 | — | — | US | disclosed |
| WO-2004067482-A2 | SUBSTITUTED ANILIDE LIGANDS FOR THE THYROID RECEPTOR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180940-A1 | Substituted anilide ligands for the thyroid receptor | TSHR, TRHR, THRA | THRB 4/4885THRA 3/4885RORC 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.